BACKGROUND:PIK3CA gene encodes the p110 α catalytic subunit of the oncoprotein phosphatidylinositol 3-kinase (PI3 K) which regulates many biological processes such as cell proliferation, differentiation, migration and survival through the activation of various signaling pathways.
OBJECTIVE: In this study, we have investigated the possible somatic mutations in PIK3CA gene in invasive ductal breast carcinomas of Chinese women from Western China.
METHODS: Genomic DNA was extracted from the formalin-fixed paraffin-embedded(FFPE) tissue samples. The hotspot mutations in PIK3CA gene of exon 9 and exon 20 were studied by pyrosequencing.
RESULTS: The sequencing identified two hotspot mutations in exon 20 of one cancer samples at p. H1047L (c. 3140A > T) and eight cancer sample at p. H1047R(c. 3140A > G). No mutation in exon 9 of PIK3CA gene was found in these breast cancer tissue samples. PIK3CA mutations showed surprising clinicopathological features in breast cancer patients, as incidence of lymph node invasiveness is increased in the patients with PIK3CA mutation. In addition, all the patients showed tumor size bigger than 3 cm in diameter. It is important that for early detection and early treatment for BC in developing countries or areas like Western China, and for people to provide popularization education using scientific knowledge in cancer fields.
CONCLUSIONS: This study identified PIK3CA mutations in breast carcinoma patients of Western China that will enable a more rapid molecular diagnosis, and provide a stronger rationale evidence for development of precision therapeutic approaches as well as promising therapeutic targets for breast cancer treatment or patient management.
VivancoI. and SawyersC.L., The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nature Reviews Cancer2 (2002), 489-501.
2.
CantleyL.C., The phosphoinositide 3-kinase pathway, Science296 (2002), 1655-1657.
3.
LiS.Y., RongM., GrieuF. and Iacopetta BB., PIK3CA mutations in breast cancer are associated with poor outcome, Breast Cancer Research and Treatment96 (2006), 91-95.
4.
YuanZ.Q., SunM., FeldmanR.I., WangG., MaX., JiangC. et al., Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer, Oncogene19 (2000), 2324-2330.
5.
SamuelsY., WangZ., BardelliA., SillimanN., PtakJ., SzaboS. et al., High frequency of mutations of the PIK3CA gene in human cancers, Science304 (2004), 554.
6.
LiuS., WangH., ZhangL., TangC., JonesL., YeH., et al., Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing, Human Genomics9 (2015), 2.
7.
ImaniS., HosseinifardH., ChengJ., WeiC. and FuJ., Prognostic value of EMT-inducing transcription factors (EMT-TFs) in metastatic breast cancer: A systematic review and meta-analysis, Scientific Reports6 (2016), 6.
8.
FanL., Strasser-WeipplK., LiJ.J., St LouisJ., FinkelsteinD.M., YuK.D., ChenW.Q., ShaoZ.M. and GossP.E., Breast cancer in China, Lancet Oncology15 (2014), e279-e289.
9.
BaiX., ZhangE., YeH., NandakumarV., WangZ., ChenL., et al., PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing, PLoS One9 (2014), e99306.
10.
AgarwalG., RamakantP., ForgachE.R., RendónJ.C., ChaparroJ.M., BasurtoC.S. and MargaritoniM., Breast cancer care in developing countries, World Journal of Surgery33 (2009), 2069-2076.
11.
BrodyJ.G., RudelR.A., MichelsK.B., MoysichK.B., BernsteinL., AttfieldK.R. and GrayS., Environmental pollutants, diet, physical activity, body size, and breast cancer: Where do we stand in research to identify opportunities for prevention? Cancer109 (2007), 2627-2634.
12.
KadotaM., SatoM., DuncanB., OoshimaA., YangH.H., Diaz-MeyerN. et al., Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA, Cancer Research69 (2009), 7357-7365.
13.
WeiC., ChengJ., ZhouB., ZhuL., KhanM.A., HeT. et al., Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein, Scientific Reports6 (2016), 29822.
14.
FuJ., ZhangL., HeT., XiaoX., LiuX., WangL., YangL. et al., TWIST Represses Estrogen Receptor-alpha Expression by Recruiting the NuRD Protein Complex in Breast Cancer Cells, International Journal of Biological Sciences8 (2012), 522-532.
15.
KhanM.A., ZhuL., TaniaM., XiaoX. and FuJ., Relationship between SPOP mutation and breast cancer in Chinese population, Genetic and Molecular Research14 (2015), 12362-12366.
16.
KhanM.A., TaniaM., WeiC., MeiZ., FuS., ChengJ., XuJ. and FuJ., Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition, Oncotarget6 (2015), 19580-19591.
17.
SuetaA., YamamotoY., Yamamoto-IbusukiM., HayashiM., TakeshitaT., YamamotoS. and IwaseH., An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer, PLoS One9 (2014), e116054.
18.
López-KnowlesE., SegalC.V., GaoQ., Garcia-MurillasI., TurnerN.C., SmithI., MartinL.A. and DowsettM., Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition, Breast Cancer Research16 (2014), R68.
19.
ManceauG., MarisaL., BoigeV., DuvalA., GaubM.P., MilanoG. et al., PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer, Cancer Medicine4 (2015), 371-382.
20.
VoliniaS., HilesI., OrmondroydE., NizeticD., AntonacciR., RocchiM. and WaterfieldM.D., Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene, Genomics24 (1994), 472-477.
21.
ZardavasD., PhillipsW.A. and LoiS., PIK3CA mutations in breast cancer: Reconciling findings from preclinical and clinical data, Breast Cancer Research16 (2014), 201.
22.
DiricanE., KayaZ., GulluG., PekerI., OzmenT., GulluogluB.M., KayaH., OzerA. and AkkiprikM., Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer, Asian Pacific Journal of Cancer Prevention15 (2014), 9327-9333.
23.
LeeJ.W., SoungY.H., KimS.Y., LeeH.W., ParkW.S., NamS.W. et al., PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas, Oncogene24 (2005), 1477-1480.
24.
YuanK., WuH., WangY., ChenH., JiaoM. and FuR., Phospho-PRAS40 (Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer, Oncology Letters9 (2015), 785-789.
25.
WuG., XingM., MamboE., HuangX., LiuJ. et al., Somatic mutation and gain of copy number of PIK3CA in human breast cancer, Breast Cancer Research7 (2005), R609-R616.
26.
BachmanK.E., ArganiP., SamuelsY., SillimanN., PtakJ., SzaboS. et al., The PIK3CA gene is mutated with high frequency in human breast cancers, Cancer Biology & Therapy3 (2004), 772-775.
27.
SaalL.H., HolmK., MaurerM., MemeoL., SuT., WangX. et al., PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma, Cancer Research65 (2005), 2554-2559.
28.
DiricanE., AkkiprikM. and ÖzerA., Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer, Tumor Biology37 (2016), 7033-7045.
29.
ZhangL., YangM., GanL., HeT., XiaoX., StewartM.D. et al., DLX4 upregulates TWIST and enhances tumor migration, invasion and metastasis, International Journal of Biological Sciences8 (2012), 1178-1187.
30.
EllisM.J., DingL., ShenD., LuoJ., SumanV.J., WallisJ.W. et al., Whole-genome analysis informs breast cancer response to aromatase inhibition, Nature486 (2012), 353-360.
31.
MullerK.E., MarottiJ.D., de AbreuF.B., PetersonJ.D., MillerT.W., ChamberlinM.D. et al., Targeted next-generation sequencing detects a high frequency of potentially actionable mutationsin metastatic breast cancers, Experimental and Molecular Pathology100 (2016), 421-425.
32.
Perez-TenorioG., AlkhoriL., OlssonB., WalterssonM.A., NordenskjoldB., RutqvistL.E., SkoogL. and StalO., PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer, Clinical Cancer Research13 (2007), 3577-3584.
33.
BarbareschiM., ButtittaF., FelicioniL., CotrupiS., BarassiF., Del GrammastroM. et al., Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas, Clinical Cancer Research13 (2007), 6064-6069.
34.
KalinskyK., JacksL.M., HeguyA., PatilS., DrobnjakM., BhanotU.K. et al., PIK3CA mutation associates with improved outcome in breast cancer, Clinical Cancer Research15 (2009), 5049-5059.
35.
JensenJ.D., KnoopA., LaenkholmA.V., GrauslundM., JensenM.B., Santoni-RugiuE. et al., PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab, Annals of Oncology23 (2012), 2034-2042.
36.
Lopez-KnowlesE., O'TooleS.A., McNeilC.M., MillarE.K., QiuM.R., CreaP. et al., PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality, International Journal of Cancer126 (2010), 1121-1131.
37.
LoiS., MichielsS., LambrechtsD., FumagalliD., ClaesB., Kellokumpu-LehtinenP.L. et al., Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer, Journal of the National Cancer Institute105 (2013), 960-967.
38.
MajewskiI.J., NuciforoP., MittempergherL., BosmaA.J., EidtmannH., HolmesE. et al., PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer, Journal of Clinical Oncology33 (2015), 1334-1339.
39.
TurturroS.B., NajorM.S., RubyC.E., CobleighM.A. and AbukhdeirA.M., Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin, Breast Cancer Research and Treatment156 (2016) 33-43.
40.
SarkerD., AngJ.E., BairdR., KristeleitR., ShahK., MorenoV. et al., First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors, Clinical Cancer Research21 (2015) 77-86.
41.
BendellJ.C., RodonJ., BurrisH.A., de JongeM., VerweijJ., BirleD. et al., Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors, Journal of Clinical Oncology30 (2012), 282-290.
